talipexole

Talipexole (B-HT 920) is a synthetic small molecule dopamine agonist that acts primarily at dopamine D2 receptors with agonist activity at both pre- and post-synaptic sites, as well as agonist activity at alpha-2 adrenoceptors and antagonist activity at 5-HT3 serotonin receptors. It is structurally characterized as an azepine derivative. Talipexole has been marketed under the brand name Domnin in Japan as an antiparkinsonian medication and has also been investigated for its effects on negative symptoms of schizophrenia. Its mechanism of action includes stimulation of dopaminergic signaling, inhibition of presynaptic dopamine release via autoreceptor activation, α2-adrenergic receptor agonism, and selective blockade of 5-HT3 serotonin channels. Talipexole was developed by Boehringer Ingelheim, introduced in Japan in 1996 and has not been approved in the US or Europe[1][3][4][5][6][7][8].

Brand names

Domnin

Other names

talipexole dihydrochloride6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepin-2-amine dihydrochloride5,6,7,8-tetrahydro-6-(2-propenyl)-4H-thiazolo[4,5-d]azepine-2-amine dihydrochloride